Metabolomic Profiles Delineate Signature Metabolic Shifts during Estrogen Deficiency-Induced Bone Loss in Rat by GC-TOF/MS

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ma, Bo ^a   Liu, Jiannan ^b   Zhang, Qi ^a   Ying, Hanjie ^a   Jiye, A ^c   Sun, Jianguo ^c   Wu, Di ^d,e   Wang, Yonglu ^a   Li, Jing ^a   Liu, Yinhui ^a  

^a NANJING TECH UNIVERSITY   (China)

^b Jiangsu Geriatric Hospital   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ESTROGEN; HOMOCYSTEINE; HYDROXYPROLINE; ISOLEUCINE; LAURIC ACID; LEUCINE; LINOLEIC ACID; LYSINE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; BONE DENSITY; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE COURSE; ESTROGEN DEFICIENCY; FEMALE; GAS CHROMATOGRAPHY; METABOLOMICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PARTIAL LEAST SQUARES REGRESSION; POSTMENOPAUSE OSTEOPOROSIS; PRINCIPAL COMPONENT ANALYSIS; RAT; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BODY WEIGHT; BONE DENSITY; ESTROGENS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; METABOLOMICS; OSTEOPOROSIS; OVARIECTOMY; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84873573215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054965     Document Type: Article

References (53)

1. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, et al. (2001) Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 286: 815-820.
2. Hillier TA, Stone KL, Bauer DC, Rizzo JH, Pedula KL, et al. (2007) Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 167: 155-160.
3. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, et al. (2012) Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 366: 225-233.
4. Kahl KG, Rudolf S, Stoeckelhuber BM, Dibbelt L, Gehl HB, et al. (2005) Bone mineral density, markers of bone turnover, and cytokines in young women with borderline personality disorder with and without comorbid major depressive disorder. Am J Psychiatry 162: 168-174.
5. Bhattacharyya S, Siegel ER, Achenbach SJ, Khosla S, Suva LJ, (2008) Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res 23: 1106-1117.
6. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, et al. (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42: 832-836.
7. Vasikaran SD, (2008) Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 45: 221-258.
8. Abe Y, Ishikawa H, Fukao A, (2008) Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. Tohoku J Exp Med 214: 51-59.
9. Nicholson JK, Lindon JC, (2008) Systems biology: Metabonomics. Nature 455: 1054-1056.
10. Leslie RD, Beyan H, (2011) Metabolomics makes a mark: early changes associated with autoimmune diabetes. Diabetes 60: 2688-2690.
11. Patel VR, Eckel-Mahan K, Sassone-Corsi P, Baldi P, (2012) CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics. Nat Methods 9: 772-773.
12. Patti GJ, Yanes O, Siuzdak G, (2012) Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13: 263-269.
13. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
14. Patti GJ, Yanes O, Shriver LP, Courade JP, Tautenhahn R, et al. (2012) Metabolomics implicates altered sphingolipids in chronic pain of neuropathicorigin. Nat Chem Biol 8: 232-234.
15. Shi X, Yao D, Chen C, (2012) Identification of N-Acetyltaurine as a Novel Metabolite of Ethanol throughMetabolomics-guided Biochemical Analysis. J Biol Chem 287: 6336-6349.
16. Chen C, Shah YM, Morimura K, Krausz KW, Miyazaki M, et al. (2008) Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab 7: 135-147.
17. Bonnelye E, Aubin JE, (2005) Estrogen receptor-related receptor alpha: a mediator of estrogen response in bone. J Clin Endocrinol Metab 90: 3115-3121.
18. Hofbauer LC, Schoppet M, (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490-495.
19. Pacifici R, Vannice JL, Rifas L, Kimble RB, (1993) Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J Clin Endocrinol Metab 77: 1135-1141.
20. Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y, (2009) Oxidative stress in bone remodelling and disease. Trends Mol Med 15: 468-477.
21. Lu Y, A J, Wang G, Hao H, Huang Q, et al. (2008) Gas chromatography/time-of-flight mass spectrometry based metabonomic approach to differentiating hypertension- and age-related metabolic variation in spontaneously hypertensive rats. Rapid Commun Mass Spectrom 22: 2882-2888.
22. Zhang Q, Wang G, A J, Ma B, Dua Y, et al. (2010) Metabonomic profiling of diet-induced hyperlipidaemia in a rat model. Biomarkers 15: 205-216.
23. A J, Qian S, Wang G, Yan B, Zhang S, et al. (2010) Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. PLOS ONE 5: e13186.
24. Yan B, A J, Wang G, Lu H, Huang X, et al. (2009) Metabolomic investigation into variation of endogenous metabolites in professional athletes subject to strength-endurance training. J Appl Physiol 106: 531-538.
25. Ma B, Zhang Q, Wang GJ, A JY, Wu D, et al. (2011) GC-TOF/MS-based metabolomic profiling of estrogen deficiency-induced obesity in ovariectomized rats. Acta Pharmacol Sin 32: 270-278.
26. Liu L, Aa J, Wang G, Yan B, Zhang Y, et al. (2010) Differences in metabolite profile between blood plasma and serum. Anal Biochem 406: 105-112.
27. A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, et al. (2005) Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem 77: 8086-8094.
28. Jonsson P, Johansson AI, Gullberg J, Trygg J, A J, et al. (2005) High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal Chem 77: 5635-5642.
29. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD, (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11: 337-349.
30. Ma B, Zhang Q, Wu D, Wang YL, Hu YY, et al. (2012) Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin 33: 479-489.
31. Patel MI, Kurek C, Dong Q, (2008) The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 179: 1668-1675.
32. Zordoky BN, El-Kadi AO, (2010) Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 125: 446-463.
33. Harizi H, Corcuff JB, Gualde N, (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 14: 461-469.
34. Coetzee M, Haag M, Kruger MC, (2007) Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. J Nutr Biochem 2007 18: 54-63.
35. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I, (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57: 684-694.
36. Pacifici R, Rifas L, Teitelbaum S, Slatopolsky E, McCracken R, et al. (1987) Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A 84: 4616-4620.
37. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, Gram J, Beck-Nielsen H, (2000) Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res 15: 1545-1554.
38. Watkins BA, Li Y, Allen KG, Hoffmann WE, Seifert MF, (2000) Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr 130: 2274-2284.
39. Weiss LA, Barrett-Connor E, von Mühlen D, (2005) Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am J Clin Nutr 81: 934-938.
40. Omoigui S, (2005) Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med Hypotheses 65: 559-569.
41. Parhami F, Mody N, Gharavi N, Ballard AJ, Tintut Y, (2002) Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J Bone Miner Res 17: 1997-2003.
42. You L, Sheng ZY, Tang CL, Chen L, Pan L, et al. (2011) High cholesterol diet increases osteoporosis risk via inhibiting bone formation in rats. Acta Pharmacol Sin 32: 1498-1504.
43. Ma YL, Bryant HU, Zeng Q, Palkowitz A, Jee WS, et al. (2002) Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res 17: 2256-2264.
44. Whitney C, Warburton DE, Frohlich J, Chan SY, McKay H, et al. (2004) Are cardiovascular disease and osteoporosis directly linked. Sports Med 34: 779-807.
45. Jinno Y, Ayukawa Y, Ogino Y, Atsuta I, Tsukiyama Y, et al. (2009) Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study. Clin Oral Implants Res 20: 756-760.
46. Spencer TA, Chai H, Fu W, Ramaswami G, Cox MW, et al. (2004) Estrogen blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Surg Res 118: 83-90.
47. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, et al. (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350: 2042-2049.
48. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, et al. (2006) Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 21: 1003-1011.
49. Dimitrova KR, DeGroot K, Myers AK, Kim YD, (2002) Estrogen and homocysteine. Cardiovasc Res 53: 577-588.
50. Bayhan I, Uygur D, Ugurlu N, Ozaksit G, (2009) Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women. Rheumatol Int 29: 263-266.
51. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, et al. (2001) Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184: 350-353.
52. Ferrandez L, Martin M, Fernandez M, (1990) Calcitonin, estradiol, and hydroxyproline as parameters in the early diagnosis of involutional osteoporosis. The importance of the "second calcitonin phenomenon". Arch Orthop Trauma Surg 109: 181-185.
53. Schmolke B, (2001) Laboratory diagnosis of osteoporosis. Orthopade 30: 425-436.